← Back to Screener
Amicus Therapeutics, Inc (FOLD)
Price$14.49
Value ScoreD
Growth ScoreC
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)65.15%
Price vs S&P 500 (4W)-12.75%
VGM Score46.04
Market Capitalization$4.55B
All Metrics
P/CF (Annual)137.27x
Book Value / Share (Quarterly)$0.88
P/TBV (Annual)16.92x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)24.43%
Cash Flow / Share (Quarterly)$0.10
Price vs S&P 500 (YTD)-3.12%
Gross Margin (TTM)88.50%
Net Profit Margin (TTM)-4.27%
EPS (TTM)$-0.09
10-Day Avg Trading Volume2.89M
EPS Excl Extra (TTM)$-0.09
Revenue Growth (5Y)19.44%
EPS (Annual)$-0.09
ROI (Annual)-4.07%
Gross Margin (Annual)88.50%
Net Profit Margin (5Y Avg)-41.34%
Cash / Share (Quarterly)$0.94
Revenue Growth QoQ (YoY)23.72%
ROA (Last FY)-2.85%
Revenue Growth TTM (YoY)20.05%
EBITD / Share (TTM)$0.13
ROE (5Y Avg)-81.46%
Operating Margin (TTM)5.17%
Cash Flow / Share (Annual)$0.10
P/B Ratio16.59x
P/B Ratio (Quarterly)16.06x
Net Income / Employee (Annual)$-53,100
EV / Revenue (TTM)7.46x
Net Interest Coverage (TTM)1.00x
ROA (TTM)-3.17%
EPS Growth QoQ (YoY)-88.57%
EV / EBITDA (TTM)117.48x
EPS Incl Extra (Annual)$-0.09
Current Ratio (Annual)2.84x
Quick Ratio (Quarterly)1.72x
3-Month Avg Trading Volume8.16M
52-Week Price Return-7.35%
EV / Free Cash Flow (Annual)158.41x
Revenue / Employee (TTM)$1,241,100
Tangible BV / Share (Quarterly)$0.84
P/S Ratio (Annual)7.17x
Asset Turnover (Annual)0.67x
52-Week High$14.50
Operating Margin (5Y Avg)-29.01%
EPS Excl Extra (Annual)$-0.09
CapEx CAGR (5Y)0.41%
Tangible BV CAGR (5Y)-0.23%
26-Week Price Return71.68%
Quick Ratio (Annual)1.72x
13-Week Price Return1.54%
Total Debt / Equity (Annual)1.43x
Current Ratio (Quarterly)2.84x
Enterprise Value$4.73B
Revenue / Share Growth (5Y)15.34%
Asset Turnover (TTM)0.74x
Book Value / Share Growth (5Y)-4.19%
Revenue / Employee (Annual)$1,241,100
Inventory Turnover (Annual)0.42x
Pretax Margin (Annual)0.03%
Cash / Share (Annual)$0.94
3-Month Return Std Dev1.71%
Gross Margin (5Y Avg)89.22%
Net Income / Employee (TTM)$-53,100
ROE (Last FY)-9.89%
Net Interest Coverage (Annual)1.00x
EPS Basic Excl Extra (Annual)$-0.09
P/FCF (TTM)77.41x
Receivables Turnover (TTM)5.86x
EV / Free Cash Flow (TTM)158.41x
Total Debt / Equity (Quarterly)1.43x
EPS Incl Extra (TTM)$-0.09
Receivables Turnover (Annual)5.86x
ROI (TTM)-4.39%
P/S Ratio (TTM)7.17x
Pretax Margin (5Y Avg)-39.12%
Revenue / Share (Annual)$2.06
Tangible BV / Share (Annual)$0.84
Forward P/E39.70x
Price vs S&P 500 (52W)-18.16%
Year-to-Date Return1.76%
5-Day Price Return0.21%
EPS Normalized (Annual)$-0.09
ROA (5Y Avg)-17.97%
Net Profit Margin (Annual)-4.27%
Month-to-Date Return0.21%
Cash Flow / Share (TTM)$-0.57
EBITD / Share (Annual)$0.13
Operating Margin (Annual)5.17%
LT Debt / Equity (Annual)1.43x
P/CF (TTM)137.27x
ROI (5Y Avg)-24.64%
LT Debt / Equity (Quarterly)1.43x
EPS Basic Excl Extra (TTM)$-0.09
P/TBV (Quarterly)16.92x
P/B Ratio (Annual)16.06x
Inventory Turnover (TTM)0.42x
Pretax Margin (TTM)0.03%
Book Value / Share (Annual)$0.88
Price vs S&P 500 (13W)-2.22%
Beta0.22x
P/FCF (Annual)152.43x
Revenue / Share (TTM)$2.05
ROE (TTM)-12.02%
52-Week Low$5.51
vGradeD
gGradeC
mGradeB
vgmGradeC
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.57
3.57
3.57
3.57
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
FOLDAmicus Therapeutics, Inc | D | C | B | $14.49 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Amicus Therapeutics develops precision medicines for rare genetic diseases. Its pipeline includes an oral treatment for Fabry disease, a clinical-stage therapy for Pompe disease, and a rare disease gene therapy platform. The company targets high-impact orphan diseases with limited treatment options.